Authors

XI CHEN, CHENGHAI TANG, YILIN CAO, GAOJUAN LIN, HUILING ZHAO, LIAN DENG

Departments

Department of Oncology, Nanxishan Hospital, Guangxi Zhuang Autonomous Region, Deputy Chief Physician, 541002 China

Abstract

Objective: Cervical cancer has become the second most common malignancy of women in the world with its high incidence, high invasiveness, high metastasis, and gradual rejuvenation. The prognosis of patients with cervical cancer has closely related to its stage. For invasive metastasis, the prognosis is relatively poor, and the prognosis of those with limited tumor is relatively good.

Methods: At present, the treatment of cancer is gradually becoming an era of individualized treatment, which emphasizes systemic therapy. Detection of specific tumor molecular markers is an important basis for identifying individual differences in tumor patients, and it is the premise and basis for individualized treatment of tumors. This paper has selected suitable drugs for patients.

Results: This paper has also randomly selected pathological specimens of 80 newly diagnosed cervical cancer patients with pathologically confirmed and complete clinical data in our hospital as the study group. Immunohistochemistry has used to detect the expression of nesting in cervical cancer tissue and to investigate its expression in cervical cancer. 60 patients are selected and pathological specimens of newly diagnosed cervical cancer patients were divided into two groups according to the efficacy of chemotherapy: chemotherapy effective group and chemotherapy ineffective group, 30 cases in each group. The nestin expression level of interstitial markers has compared between the two groups.

Conclusions: Through the comparison of nestin expression levels of interstitial markers between the two groups. This paper provides personalized predictive indicators for patients with personalized adjuvant chemotherapy, worthy of clinical application.

Keywords

Cervical neoplasms, N-cadherin, Cisplatin chemotherapy, Immunohistochemistry

DOI:

10.19193/0393-6384_2018_6_258